Navigation Links
Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
Date:4/23/2013

he pendency of the acquisition; the risk that the operations of the two companies will not be integrated successfully; and other risks and uncertainties, including those detailed from time to time in the companies' periodic reports filed with the Securities and Exchange Commission ("SEC") and in the case of Valeant, the Canadian Securities Administrators ("CSA"), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "RISK FACTORS" in their annual reports on Form 10-K for the year ended December 31, 2012, which have been filed with the SEC and in the case of Valeant, the CSA. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the companies' actual results to differ materially from expected and historical results. The companies assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Additional Information and Where to Find It
This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Obagi. Valeant filed a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission on March 26, 2013, as amended on April 4, 2013, April 5, 2013, April 12, 2013 and April 22, 2013. Obagi filed a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer on March 26, 2013, as amended on April 2, 2013, April 3, 2013, April 4, 2013, April 5, 2013, April 12, 2013 and April 22, 2013.   Stockholders and other investors are urged to read the tender offer materials (including the Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, in each case as amended (to the extent applicable), because they contain important inform
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
2. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
3. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
4. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
5. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
6. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
7. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
8. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
9. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
10. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
11. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2015  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual ... of intellectual property, today announced a litigation update. ... Verizon Services Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, ... District of Virginia , the Court ... certain key claims in favor of the Defendants on ...
(Date:7/2/2015)... Memphis, TN (PRWEB) , ... July 02, 2015 ... ... in the development and manufacturing of surgical instruments in Orthopedics, announced today the ... orthopedic contract-manufacturing and the world's largest provider of surgical instruments to the Spine ...
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus ... the development of groundbreaking drugs to treat neurodegenerative ... today that Robert G. Miller , M.D., Director ... Sutter Health,s California Pacific Medical Center in San Francisco, ... Association for $1.5 million to help fund a ...
Breaking Biology Technology:Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
... June 2 Repligen Corporation (Nasdaq: RGEN ) announced today ... year 2010, on Wednesday, June 9th, 2010 , before the market opens. ... will host a conference call and webcast on the same day at ... update on the Company. , , ...
... SHANGHAI , June 2 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,("China-Biotics", the ... products in China , today announced,it will host a conference call ... 2010 , to discuss the fourth quarter and fiscal year 2010 annual,financial ... , , ...
... SHANGHAI , June 2 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc.,("China-Biotics", the ... in China , today announced,that its management will present at the Bank ... Tuesday, June 22, 2010 at the Merrill,Lynch Client Service Center in ... ...
Cached Biology Technology:Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 3China-Biotics to Report Fourth Quarter and Fiscal Year 2010 Financial Results on June 11 2China-Biotics to Present at Bank of America Merrill Lynch Healthcare Event on June 22 2
(Date:6/11/2015)... , June 11, 2015 Daon, ... announced today that its IdentityX Mobile Authentication Platform ... IDentity Online) Alliance is an industry consortium launched ... standards for simpler, stronger authentication.  In order to ... pass a rigorous series of tests that measure ...
(Date:6/9/2015)... , June 9, 2015   MedNet Solutions ... the entire spectrum of clinical research, will be providing ... technology platform at the 2015 Drug Information Association (DIA) ... on June 15-17.  These presentations will include previews of ... out in the upcoming iMedNet 2015 Feature ...
(Date:6/8/2015)... , June 8, 2015  Trovagene, Inc. (NASDAQ: TROV ... clinical data featuring its Precision Cancer Monitoring SM platform ... Liquid Biopsies conference in San Diego, CA ... Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy ... June 13-16. "We continue to advance our ...
Breaking Biology News(10 mins):Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4
... populating the growing brain, neural stem cells must strike a ... the cells multiply to provide plenty of starting materials ... If the stem cells proliferate too much, they could ... proliferate too little, there may not be enough cells to ...
... / b3c newswire / - KINAXO Biotechnologies GmbH ... service portfolio. KinAffinity provides invaluable information about a ... of interest. It simultaneously determines affinities for native ... overcomes the limitations of traditional biochemical assays that ...
... of researchers from the University of Maryland Center for ... study to forecast the effects of environmental change on ... by a $620,000 grant from the National Science Foundation, ... Preserve near Alexandria, Virginia. "Freshwater marshes are integral ...
Cached Biology News:UNC study pinpoints gene controlling number of brain cells 2KINAXO launches KinAffinity services for efficient profiling of kinase inhibitors in cells or tissue 2